A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

Key facts

Sponsor

Teva Branded Pharmaceutical Products R&D LLC

Principal Investigator

Tev Medical Expert, Study Director

Teva Branded Pharmaceutical Products R&D LLC

Intervention

TEV-56286(drug)

Enrollment

350 target

Eligibility

30-75 years · All sexes

Timeline

2024 – 2027

Study locations (30)

• Teva Investigational Site 15554, La Jolla, California, United States
• Teva Investigational Site 15545, Los Angeles, California, United States
• Teva Investigational Site 15547, Washington D.C., District of Columbia, United States
• Teva Investigational Site 15544, Boca Raton, Florida, United States
• Teva Investigational Site 15555, Tampa, Florida, United States
• Teva Investigational Site 15550, Chicago, Illinois, United States
• Teva Investigational Site 15546, Kansas City, Kansas, United States
• Teva Investigational Site 15736, Boston, Massachusetts, United States
• Teva Investigational Site 15870, Farmington Hills, Michigan, United States
• Teva Investigational Site 15552, Rochester, Minnesota, United States
• Teva Investigational Site 15549, New York, New York, United States
• Teva Investigational Site 15551, New York, New York, United States
• Teva Investigational Site 15553, Durham, North Carolina, United States
• Teva Investigational Site 15735, Hershey, Pennsylvania, United States
• Teva Investigational Site 15548, Pittsburgh, Pennsylvania, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Multiple system atrophy

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07446894
  MSA-01 in Multiple System Atrophy
  Tokyo University
• RECRUITINGPHASE2NCT07197866
  An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
  Teva Branded Pharmaceutical Products R&D LLC
• ENROLLING BY INVITATIONNCT07081841
  AB-1005 Long-Term Follow-up Study
  AskBio Inc
• RECRUITINGPHASE1, PHASE2NCT06831500
  Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease.
  Julien Bally
• RECRUITINGEARLY PHASE1NCT06765733
  The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy
  Beijing Tiantan Hospital
• RECRUITINGPHASE2NCT06868628
  A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
  Tiziana Life Sciences LTD
• RECRUITINGNCT07353463
  Shanghai Clinical Cohort - Parkinson's Disease (Reserve)
  Ruijin Hospital
• RECRUITINGEARLY PHASE1NCT06891703
  [18F]ACI-15916 PET in α-synucleinopathies
  AC Immune SA

See all trials for Multiple system atrophy →